Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.74 USD
Change Today +0.0401 / 2.36%
Volume 157.0K
MEIP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 12:28 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

mei pharma inc (MEIP) Snapshot

Open
$1.70
Previous Close
$1.70
Day High
$1.75
Day Low
$1.69
52 Week High
10/13/14 - $8.33
52 Week Low
06/16/15 - $1.65
Market Cap
59.4M
Average Volume 10 Days
432.2K
EPS TTM
$-1.48
Shares Outstanding
34.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEI PHARMA INC (MEIP)

Related News

No related news articles were found.

mei pharma inc (MEIP) Related Businessweek News

No Related Businessweek News Found

mei pharma inc (MEIP) Details

MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. Its clinical development pipeline also includes ME-344, an isoflavone-derived mitochondrial inhibitor drug candidate that is in Phase Ib trial to treat lung and ovarian cancer; and PWT143, an oral inhibitor of phosphatidylinositide 3-kinase, which is in pre-clinical stage for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited.

19 Employees
Last Reported Date: 09/9/14
Founded in 2000

mei pharma inc (MEIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $482.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $284.6K
Chief Medical Officer
Total Annual Compensation: $153.6K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $70.6K
Compensation as of Fiscal Year 2014.

mei pharma inc (MEIP) Key Developments

MEI Pharma, Inc. Reports Updated Results from Phase II Study of Pracinostat and Azacitidine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

MEI Pharma, Inc. announced updated results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza) in elderly patients with newly diagnosed acute myeloid leukemia (AML). Data from 50 patients treated at 15 centers are being presented at the European Hematology Association (EHA) Annual Congress in Vienna. To date, 27 of 50 patients (54%) have achieved the primary endpoint of complete response (CR) plus complete response with incomplete blood count recovery (CRi) plus morphologic leukemia-free state (MLFS), including 16 patients (32%) who achieved a CR. The response rate from this study compares favorably with previous studies of azacitidine alone in this population1. Most responses occur within the first two cycles and continue to improve with ongoing therapy. Median overall survival has not yet been reached in the study, with 32 patients (64%) still being followed (range, 6-15 months). Survival of patients with intermediate-risk cytogenetic abnormalities appears greater than that for patients with high-risk cytogenetics, though neither subset of patients has reached median survival. The 60-day mortality rate, often used as a benchmark in AML clinical studies, was 10% (5 of 50). Pracinostat in combination with azacitidine was well tolerated in this population of elderly AML patients. The most common treatment-emergent adverse events (AEs) included febrile neutropenia, thrombocytopenia, nausea and fatigue. AEs resulting in dose reductions were frequently due to disease under study. Nearly half of the patients (22 of 50) to date have received study drug beyond six months, reflecting long-term tolerability.

MEI Pharma, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 08:00 AM

MEI Pharma, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 08:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Daniel P. Gold, Chief Executive Officer, President and Director.

MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies

MEI Pharma, Inc. announced new pre-clinical data showing mitochondria-specific effects of the company's investigational drug candidate ME-344 in cancer cells, including significantly enhanced anti-tumor activity when combined with a tyrosine-kinase inhibitor (TKI). In addition, a recently published study found ME-344 to be a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, a direct molecular target. In a paper published in the most recent issue of American Journal of Cancer Research1, the company's collaborators at the MIMR-PHI Institute of Medical Research in Melbourne identified mitochondrial OXPHOS complex I as a direct molecular target of ME-344, its inhibition causing an immediate reduction of mitochondrial oxygen consumption. To gain further insight into its mechanism of action, researchers at the Medical University of South Carolina in Charleston compared the activity of ME-344 in sensitive and naturally resistant lung cancer cell lines. In a dose dependent manner, ME-344 caused instantaneous and pronounced inhibition of oxygen consumption rates in drug-sensitive lung cancer cells, but significantly less in drug-resistant cells. Notably, drug resistance correlated with higher glycolytic metabolism in these cells. Using a well-characterized spontaneous breast tumor model, researchers at the Spanish National Cancer Research Centre in Madrid found that chronic treatment with the small molecule TKI nintedanib (formerly BIBF 1120) significantly diminished tumor cell glycolysis, however the growing tumor shifted to reliance on mitochondrial metabolism as its primary energy source. Subsequently, tumors primed by treatment with nintedanib showed significantly enhanced sensitivity to the mitochondrial inhibitor ME-344, with synergistic anti-tumor activity.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEIP:US $1.74 USD +0.0401

MEIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MEIP.
View Industry Companies
 

Industry Analysis

MEIP

Industry Average

Valuation MEIP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEI PHARMA INC, please visit www.meipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.